
|Articles|June 15, 2004
Short-term results of custom ablation stable over 2 years
Higher-order aberrations decreased in most patients, with the change from baseline reaching up to 50%.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Regeneron receives another CRL for its Eylea 8 mg
2
Eli Lilly to acquire Adverum Biotechnologies
3
Anti-VEGF innovations in retinal disease: From molecules to medicine
4
Topcon Healthcare seeks to advance company through acquisition and new investment
5


















































.png)


